LUPIN-CELECOXIB CAPSULE
Država: Kanada
Jezik: angleščina
Source: Health Canada
Lastnosti izdelka
(SPC)
18-11-2014
Nekateri dokumenti za ta izdelek trenutno niso na voljo, pošljete lahko zahtevo v našo stranko in obvestili vas bomo takoj, ko jih bomo lahko pridobili.
Pošlji zahtevo.
Pošlji zahtevo.
Aktivna sestavina:
CELECOXIB
Dostopno od:
LUPIN PHARMA CANADA LIMITED
Koda artikla:
M01AH01
INN (mednarodno ime):
CELECOXIB
Odmerek:
100MG
Farmacevtska oblika:
CAPSULE
Sestava:
CELECOXIB 100MG
Pot uporabe:
ORAL
Enote v paketu:
100/500
Tip zastaranja:
Prescription
Terapevtsko območje:
CYCLOOXYGENASE-2 (COX-2) INHIBITORS
Povzetek izdelek:
Active ingredient group (AIG) number: 0137043001; AHFS:
Status dovoljenje:
APPROVED
Datum dovoljenje:
2014-11-17
Lastnosti izdelka
_ _
_ _
_1 of 53 _
PRODUCT MONOGRAPH
PR
LUPIN-CELECOXIB
(celecoxib)
Capsules, 100 mg and 200 mg
Non-steroidal anti-inflammatory drug (NSAID)
Lupin Pharma Canada Limited
DATE OF PREPARATION:
1155, René-Lévesque West Blvd., Suite 2500 25 July 2014
Montreal QC,
H3B 2K4
SUBMISSION CONTROL NO: 154401, 175860
_ _
_ _
_2 of 53 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT
INFORMATION.....................................................................3
INDICATIONS AND CLINICAL
USE...........................................................................3
CONTRAINDICATIONS
................................................................................................4
WARNINGS AND
PRECAUTIONS...............................................................................5
ADVERSE
REACTIONS................................................................................................14
DRUG
INTERACTIONS................................................................................................22
DOSAGE AND
ADMINISTRATION...........................................................................25
OVERDOSAGE...............................................................................................................27
ACTION AND CLINICAL
PHARMACOLOGY........................................................27
STORAGE AND
STABILITY.......................................................................................29
DOSAGE FORMS, COMPOSITION AND PACKAGING
.......................................30
PART II: SCIENTIFIC INFORMATION
...............................................................................31
PHARMACEUTICAL
INFORMATION.....................................................................31
CLINICAL
TRIALS.......................................................................................................32
DETAILED
PHARMACOLOGY.................................................................................40
Preberite celoten dokument
